FORT MYERS — NeoGenomics, a cancer-testing firm, grew revenues by 16% to $18.2 million in the first quarter compared to the same quarter a year ago despite uncertainty in Medicare reimbursements.
Continue reading your article with a Business Observer subscription.
What's included:
✓ Unlimited digital access to BusinessObserverFL.com
✓ E-Newspaper app, digital replica of print edition